Johnson & Johnson (NYSE: JNJ) is the latest pharma company to provide results from the trial of its COVID-19 vaccine candidate. The company
Johnson & Johnson
-(JNJ)
XNYS:JNJ
Johnson & Johnson (JNJ) Q4 2020 Earnings Call Transcript
Johnson & Johnson (NYSE: JNJ) Q4 2020 earnings call dated Jan. 26, 2021. Corporate Participants: Chris DelOrefice — Vice President, Investor Relations Alex Gorsky — Chairman
Johnson & Johnson (JNJ): Strength in ecommerce drives growth in Consumer Health
Shares of Johnson & Johnson (NYSE: JNJ) gained nearly 3% in morning trade on Tuesday after the company reported fourth quarter 2020
Johnson & Johnson (JNJ) beats market estimates in Q4
Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2020 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported fourth-quarter
Earnings calendar for the week of January 25
Leading stock indices continued the recent rally this week, with S&P 500 and Dow Jones Industrial Average setting new records helped mainly
Johnson & Johnson’s (JNJ) COVID-19 vaccine would have an edge over others without this glitch
Johnson & Johnson (NYSE: JNJ) saw its shares climb 2% on Thursday after the company reported positive results from the early-stage trials
Earnings calendar for the week of January 11
Stock markets responded positively to the latest developments in presidential election. On the heels of the Dow Jones Industrial Average achieving a
COVID vaccine: Single-dose regimen can give Johnson & Johnson (JNJ) an edge
Johnson & Johnson (NYSE: JNJ) has adopted a slow and steady approach in its COVID vaccine research, which is one of the
COVID-19 vaccine: Pfizer (PFE) and Moderna (MRNA) are ahead in the race, where are the others?
Pfizer Inc. (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA) have made significant progress in their efforts to develop a vaccine against the
Johnson & Johnson (JNJ) Q3 2020 Earnings Call Transcript
Johnson & Johnson (NYSE: JNJ) Q3 2020 earnings call dated Oct. 13, 2020 Corporate Participants: Christopher DelOrefice -- Vice President of Investor Relations Joseph
Johnson & Johnson (JNJ) Q3 earnings: Infographic
Johnson & Johnson (NYSE: JNJ) reported third-quarter 2020 financial results before the opening bell on Tuesday. The pharmaceutical giant reported a 2%
Earnings reports to watch for the week of Oct. 12
Despite uncertainties, investors kept hopes high on a COVID-related economic stimulus this week. Riding on the positive sentiments from last week, major
COVID-19 vaccine development: A look at some of the pharma companies and their progress
The COVID-19 pandemic continues to go on and while the world is slowly coming out of the previously imposed strict lockdown, things
Johnson & Johnson (JNJ) Q2 2020 Earnings Call Transcript
Johnson & Johnson (NYSE: JNJ) Q2 2020 earnings call dated July 16, 2020 Corporate Participants: Chris DelOrefice -- Vice President, Investor Relations Paul Stoffels -- Vice
Johnson & Johnson (JNJ): Postponement of procedures hits medical devices unit hard in Q2
Johnson & Johnson (NYSE: JNJ) saw revenue and earnings decline for the second quarter of 2020 but both the top and bottom
Infographic: Key numbers from Johnson & Johnson (JNJ) Q2 2020 earnings announcement
Johnson & Johnson (NYSE: JNJ) reported second quarter 2020 earnings results today. Reported sales decreased 10.8% to $18.3 billion. GAAP earnings fell
Johnson & Johnson mentioned COVID 80 times during earnings call, vs. Abbott’s 16
Global pharma giants Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) announced their earnings for Q1 2020 last week. Despite
Johnson & Johnson retaining Dividend King status lifts the overall mood of the economy
Until a couple of days back, we could only speculate on the impact of COVID-19 on the economy. Of course, the record
Johnson & Johnson (NYSE: JNJ) Q1 2020 Earnings Call Transcript
Johnson & Johnson (JNJ) Q1 2020 earnings call dated Apr. 14, 2020. Corporate Participants: Chris DelOrefice -- Vice President, Investor Relations Alex Gorsky -- Chairman, Board
A visual representation of Johnson & Johnson (JNJ) Q1 2020 earnings results
Johnson & Johnson (NYSE: JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts' expectations citing product sales
Johnson & Johnson (NYSE: JNJ) Q4 2019 Earnings Conference Call Transcript
Johnson & Johnson (NYSE: JNJ) Q4 2019 Earnings Conference Call Jan. 22, 2020 Corporate Participants: Christopher DelOrefice -- Vice President of Investor Relations Alex Gorsky -- Chairman,